CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.16B, above the global median of $1.15B
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.37%
Annual Rate
CNY 0.13Paid unknown
Payout Ratio
20.0%Sustainable
Last Ex-Dividend
Jun 18, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.53BCNY2.16B · vs all stocks (USD)
Trailing P/E
129.00xvs Biotechnology peers
Revenue (TTM)
579.37MCNY86.16M · vs all stocks (USD)
Profit Margin
21.18%vs Biotechnology peers
Beta
0.5760xvs all stocks
52-Week Change
59.15%vs all stocks
Forward Annual Dividend Yield
0.37%vs all stocks
Market Capitalization
14.53BCNY2.16B · vs all stocks (USD)
Enterprise Value
13.35BCNY1.99B · vs all stocks (USD)
Trailing P/E
129.00xvs Biotechnology peers
Forward P/E
143.33xvs Biotechnology peers
Price to Sales (TTM)
26.76xvs Biotechnology peers
Price to Book (MRQ)
10.08xvs Biotechnology peers
Enterprise to Revenue
23.05xvs Biotechnology peers
Enterprise to EBITDA
72.42xvs Biotechnology peers
Gross Margin
56.34%vs Biotechnology peers
Profit Margin
21.18%vs Biotechnology peers
Operating Margin
30.87%vs Biotechnology peers
Return on Assets (TTM)
4.80%vs Biotechnology peers
Return on Equity (TTM)
8.26%vs Biotechnology peers
Revenue (TTM)
579.37MCNY86.16M · vs all stocks (USD)
Revenue per Share (TTM)
1.42CNYUpdated Aug 21, 2026Quarterly Revenue Growth
50.40%vs Biotechnology peers
Gross Profit (TTM)
320.06MCNY47.60M · vs all stocks (USD)
EBITDA (TTM)
155.05MCNY23.06M · vs all stocks (USD)
Net Income (TTM)
122.72MCNY18.25M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
46.70%vs Biotechnology peers
Operating Cash Flow (TTM)
232.57MCNY34.59M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
26.21MCNY3.90M · vs all stocks (USD)
Forward Annual Dividend Rate
0.1300CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
0.37%vs all stocks
Trailing Annual Dividend Rate
0.1300CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.37%vs all stocks
Payout Ratio
20.00%vs Biotechnology peers
Minority Interest (Equity)
6.37MCNYFY2025 · Dec 31, 2025Revenue
525.57MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
240.60MCNYFY2025 · Dec 31, 2025Gross Profit
284.98MCNYFY2025 · Dec 31, 2025Operating Income
132.74MCNY19.74M · vs all stocks (USD)
Pre-tax Income
120.89MCNYFY2025 · Dec 31, 2025Income Tax Expense
10.83MCNYFY2025 · Dec 31, 2025Net Income
110.05MCNYFY2025 · Dec 31, 2025EBIT
132.18MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
201.21MCNYFY2025 · Dec 31, 2025Research & Development
71.59MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
33.31MCNYFY2025 · Dec 31, 2025Other Operating Expenses
1.68MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
20.13MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
11.30MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2700CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
405.58MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
405.58MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
110.05MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-548.71KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
114.21MCNYFY2025 · Dec 31, 2025Free Cash Flow
-46.33MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
620.33MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
110.05MCNYFY2025 · Dec 31, 2025Stock-based Compensation
5.39MCNYFY2025 · Dec 31, 2025Other Non-cash Items
22.71MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-14.68MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.26MCNYFY2025 · Dec 31, 2025Capital Expenditures
-160.53MCNYFY2025 · Dec 31, 2025Net Acquisitions
-45.76MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.71BCNYFY2025 · Dec 31, 2025Sale of Investments
1.88BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-40.65MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
104.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-103.56MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-34.04MCNYFY2025 · Dec 31, 2025Other Financing Charges
23.46MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-10.14MCNYFY2025 · Dec 31, 2025Shares Outstanding
400.68MSharesUpdated Aug 21, 2026Float Shares
213.25MSharesUpdated Aug 21, 2026% Held by Insiders
47.06%vs all stocks
% Held by Institutions
5.96%vs all stocks
Total Cash (MRQ)
970.53MCNY144.33M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.42CNYUpdated Aug 21, 2026Total Debt (MRQ)
233.24MCNY34.69M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1510xvs Biotechnology peers
Current Ratio (MRQ)
4.27xvs Biotechnology peers
Book Value per Share (MRQ)
3.84CNYUpdated Aug 21, 2026Total Assets
1.95BCNY290.68M · vs all stocks (USD)
Total Current Assets
1.21BCNYFY2025 · Dec 31, 2025Total Liabilities
447.26MCNYFY2025 · Dec 31, 2025Total Non-current Assets
745.08MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
191.02MCNYFY2025 · Dec 31, 2025Total Current Liabilities
256.24MCNYFY2025 · Dec 31, 2025Cash
623.73MCNYFY2025 · Dec 31, 2025Cash Equivalents
229.00KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
623.96MCNYFY2025 · Dec 31, 2025Other Short-term Investments
340.02MCNYFY2025 · Dec 31, 2025Accounts Receivable
106.06MCNYFY2025 · Dec 31, 2025Inventory
40.88MCNYFY2025 · Dec 31, 2025Accounts Payable
42.50MCNYFY2025 · Dec 31, 2025Short-term Debt
88.70MCNYFY2025 · Dec 31, 2025Long-term Debt
145.56MCNYFY2025 · Dec 31, 2025Common Stock (Book)
400.68MCNYFY2025 · Dec 31, 2025Retained Earnings
279.95MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.51BCNY224.17M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
21.46CNYUpdated Aug 21, 202652-Week High
42.98CNYUpdated Aug 21, 202652-Week Change
59.15%vs all stocks
Beta
0.5760xvs all stocks
50-Day MA
31.39CNYUpdated Aug 21, 2026200-Day MA
28.37CNYUpdated Aug 21, 2026Avg 10-Day Volume
29.46MSharesUpdated Aug 21, 2026Avg 30-Day Volume
24.89MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.3000CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.16B, above the global median of $1.15BNotable
Market cap (USD): 2,160,556,552.728Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Acro Biosystems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow
Oxford Nanopore Technologies plc
Tier 1ProductionApproval-Gated PipelineFlowInterface
Sino Biological Inc.
Tier 1ProductionApproval-Gated PipelineFlowInterface
Nuvation Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Butterfly Network Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
AnaptysBio Inc.
Tier 1ProductionApproval-Gated PipelineRiskInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Suzhou Sepax Technologies Inc.
2 interpretationsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
Medpace Holdings Inc.
2 interpretationsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
SL Corporation
2 interpretationsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth